Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATTE-2: Long-Acting Cabotegravir + Rilpivirine Maintenance
NCT02120352Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of cabotegravir, rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Apr 2014; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02120352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120352.